Aqualung Publications
Insight. Impact. Innovation.
Peer-reviewed research on eNAMPT and the ALT-100 antibody
Peer-reviewed publications on eNAMPT and the ALT-100 antibody, grouped by program. Links go to PubMed or the publisher.
Clinical studies of ALT-100
- Safety, Tolerability and Pharmacokinetics of the eNAMPT-Neutralizing ALT-100 mAb in Healthy VolunteersMiele S, et al., 2024
- Early Safety/Therapeutic Results of ALT-100 eNAMPT mAb Impact in the PUERTA Phase 2A ARDS TrialGarcia JGN, et al. Am J Respir Crit Care Med, 2026
Progressive pulmonary fibrosis
- eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary FibrosisCasanova NG, et al. Am J Respir Cell Mol Biol, 2025
Acute respiratory distress syndrome (ARDS)
- Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibodyQuijada H, et al. Eur Respir J, 2021
- eNAMPT neutralization reduces preclinical ARDS severity via rectified NFkB and Akt/mTORC2 signalingBermudez T, et al. Sci Rep, 2022
- eNAMPT Neutralization Preserves Lung Fluid Balance and Reduces Acute Renal Injury in Porcine Sepsis/VILI-Induced Inflammatory Lung InjuryFront Physiol, 2022
Bone-metastatic prostate cancer and cancer-induced bone pain
- Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic targetSun BL, et al. EBioMedicine, 2020
- A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer ProgressionSun BL, et al. Pharmaceuticals, 2021
- A humanized eNAMPT-neutralizing monoclonal antibody reduces cancer-induced bone pain and osteoclastogenesis in murine breast cancer modelMathur NC, et al. Front Pain Res, 2026
Neonatal RDS, BPD and intra-amniotic inflammation
- The eNAMPT/TLR4 inflammatory cascade drives the severity of intra-amniotic inflammation in pregnancy and predicts infant outcomesAhmed M, et al. Front Physiol, 2023
- Extracellular Nicotinamide Phosphoribosyltransferase Is a Therapeutic Target in Experimental Necrotizing EnterocolitisHalpern MD, et al. Biomedicines, 2024
Pulmonary hypertension
- Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial HypertensionChen J, et al. Circulation, 2017
- Direct Extracellular NAMPT Involvement in Pulmonary Hypertension and Vascular RemodelingSun X, et al. Am J Respir Cell Mol Biol, 2020
- Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAbAhmed M, et al. Pulm Circ, 2021
- eNAMPT/TLR4 signaling drives PAH cellular phenotypic switching and lung vascular remodelingAhmed M, et al. Cell Commun Signal, 2025
Inflammatory bowel disease and lupus vasculitis
- Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitisColombo G, et al. J Mol Med, 2020
- NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel diseaseColombo G, et al. Front Med, 2023
- eNAMPT/TLR4 inflammatory cascade activation is a key contributor to SLE Lung vasculitis and alveolar hemorrhageTurmuukhuu S, et al. J Transl Autoimmun, 2023
Research programs
- eNAMPT Is a Novel Damage-associated Molecular Pattern Protein That Contributes to the Severity of Radiation-induced Lung FibrosisGarcia AN, et al. Am J Respir Cell Mol Biol, 2022
- Involvement of eNAMPT/TLR4 signaling in murine radiation pneumonitis: protection by eNAMPT neutralizationRadiation-induced lung injury, 2021
- Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosisSun BL, et al. FASEB J, 2023
- Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancerTravelli C, et al., 2023
- eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetesMakino, et al. Diabetologia, 2024
- An eNAMPT-neutralizing mAb reduces post-infarct myocardial fibrosis and left ventricular dysfunctionCardiac fibrosis, 2024
ALT-100 is an investigational drug. It has not been approved by the FDA or any other regulatory authority.